Show simple item record

dc.contributor.authorWood, Mollie E.
dc.contributor.authorLapane, Kate L.
dc.contributor.authorFrazier, Jean A.
dc.contributor.authorYstrom, Eivind
dc.contributor.authorMick, Eric O.
dc.contributor.authorNordeng, Hedvig M.E.
dc.date2022-08-11T08:08:33.000
dc.date.accessioned2022-08-23T15:59:07Z
dc.date.available2022-08-23T15:59:07Z
dc.date.issued2016-03-01
dc.date.submitted2016-02-24
dc.identifier.citation<p>Paediatr Perinat Epidemiol. 2016 Mar;30(2):190-200. doi: 10.1111/ppe.12253. Epub 2015 Nov 3. <a href="http://dx.doi.org/10.1111/ppe.12253">Link to article on publisher's site</a></p>
dc.identifier.issn0269-5022 (Linking)
dc.identifier.doi10.1111/ppe.12253
dc.identifier.pmid26525300
dc.identifier.urihttp://hdl.handle.net/20.500.14038/30592
dc.description.abstractBACKGROUND: Triptans are commonly prescribed for migraine, a pain condition that is highly prevalent in women of childbearing age. No prior studies have investigated associations between exposure to triptans during fetal life and risk of externalising and internalising behaviours in children. METHODS: This study was set in the Norwegian Mother and Child Cohort study, a prospective birth cohort. A total of 41 173 live, singleton births without major malformations present at 36-month post-partum follow-up were included in this study; 396 used a triptan during pregnancy, 798 used a triptan prior to pregnancy only, 3291 reported migraine without triptan use, and 36 688 reported no history of migraine or triptan use. Marginal structural models were used to analyse the association between timing of triptan exposure and neurodevelopmental outcome. RESULTS: Children exposed to triptans during pregnancy had a 1.39-fold increased risk of externalising behaviours compared with those whose mothers used triptans prior to pregnancy only (95% CI 0.97, 1.97), a 1.36-fold increased risk compared with the unmedicated migraine group (95% CI 1.02, 1.81), and a 1.41-fold increased risk compared with the population comparison group (95% CI 1.08, 1.85). The greatest risk was associated with first trimester exposure (RR 1.77, 95% CI 0.98, 3.14). Risk differences were small, ranging from 3-6%. CONCLUSIONS: This study found an increased risk of clinically relevant externalising behaviours in children with prenatal exposure to triptans, and this risk was highest for first trimester exposure. Absolute risks were small, and the results may be due to confounding by underlying migraine severity.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=26525300&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4749405/
dc.subjectUMCCTS funding
dc.subjectBehavior and Behavior Mechanisms
dc.subjectClinical Epidemiology
dc.subjectEpidemiology
dc.subjectMaternal and Child Health
dc.subjectMedical Toxicology
dc.subjectPediatrics
dc.titlePrenatal Triptan Exposure and Internalising and Externalising Behaviour Problems in 3-Year-Old Children: Results from the Norwegian Mother and Child Cohort Study
dc.typeJournal Article
dc.source.journaltitlePaediatric and perinatal epidemiology
dc.source.volume30
dc.source.issue2
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/faculty_pubs/870
dc.identifier.contextkey8205594
html.description.abstract<p>BACKGROUND: Triptans are commonly prescribed for migraine, a pain condition that is highly prevalent in women of childbearing age. No prior studies have investigated associations between exposure to triptans during fetal life and risk of externalising and internalising behaviours in children.</p> <p>METHODS: This study was set in the Norwegian Mother and Child Cohort study, a prospective birth cohort. A total of 41 173 live, singleton births without major malformations present at 36-month post-partum follow-up were included in this study; 396 used a triptan during pregnancy, 798 used a triptan prior to pregnancy only, 3291 reported migraine without triptan use, and 36 688 reported no history of migraine or triptan use. Marginal structural models were used to analyse the association between timing of triptan exposure and neurodevelopmental outcome.</p> <p>RESULTS: Children exposed to triptans during pregnancy had a 1.39-fold increased risk of externalising behaviours compared with those whose mothers used triptans prior to pregnancy only (95% CI 0.97, 1.97), a 1.36-fold increased risk compared with the unmedicated migraine group (95% CI 1.02, 1.81), and a 1.41-fold increased risk compared with the population comparison group (95% CI 1.08, 1.85). The greatest risk was associated with first trimester exposure (RR 1.77, 95% CI 0.98, 3.14). Risk differences were small, ranging from 3-6%.</p> <p>CONCLUSIONS: This study found an increased risk of clinically relevant externalising behaviours in children with prenatal exposure to triptans, and this risk was highest for first trimester exposure. Absolute risks were small, and the results may be due to confounding by underlying migraine severity.</p>
dc.identifier.submissionpathfaculty_pubs/870
dc.contributor.departmentDepartment of Psychiatry
dc.contributor.departmentDepartment of Quantitative Health Sciences
dc.source.pages190-200


This item appears in the following Collection(s)

Show simple item record